PT - JOURNAL ARTICLE AU - Tawanda Chivese AU - Joshua T. Matizanadzo AU - Omran A. H. Musa AU - George Hindy AU - Luis Furuya-Kanamori AU - Nazmul Islam AU - Rafal Al-Shebly AU - Rana Shalaby AU - Mohammad Habibullah AU - Talal Al-Marwani AU - Rizeq F Hourani AU - Ahmed D Nawaz AU - Mohammad Z Haider AU - Mohamed M. Emara AU - Farhan Cyprian AU - Suhail A. R. Doi TI - The prevalence of adaptive immunity to COVID-19 and reinfection after recovery – a comprehensive systematic review and meta-analysis of 12 011 447 individuals AID - 10.1101/2021.09.03.21263103 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.03.21263103 4099 - http://medrxiv.org/content/early/2021/09/17/2021.09.03.21263103.short 4100 - http://medrxiv.org/content/early/2021/09/17/2021.09.03.21263103.full AB - Objectives This study aims to estimate the prevalence and longevity of detectable SARS-CoV-2 specific antibodies as well as memory T and B cells after recovery. In addition, the prevalence of COVID-19 reinfection, and the preventive efficacy of previous infection with SARS-CoV-2 were investigated.Methods and analyses A synthesis of existing research was conducted. The Cochrane Library for COVID-19 resources, the China Academic Journals Full Text Database, PubMed, and Scopus as well as preprint servers were searched for studies conducted between 1 January 2020 to 1 April 2021. We included studies with the relevant outcomes of interest. All included studies were assessed for methodological quality and pooled estimates of relevant outcomes were obtained in a meta-analysis using a bias adjusted synthesis method. Proportions were synthesized with the Freeman-Tukey double arcsine transformation and binary outcomes using the odds ratio (OR). Heterogeneity between included studies was assessed using the I2 and Cochran’s Q statistics and publication bias was assessed using Doi plots.Results Fifty-four studies, from 18 countries, with a total of 12 011 447 individuals, followed up to 8 months after recovery, were included. At 6-8 months after recovery, the prevalence of detectable SARS-CoV-2 specific immunological memory remained high; IgG – 90.4% (95%CI 72.2-99.9, I2=89.0%, 5 studies), CD4+ - 91.7% (95%CI 78.2 – 97.1, one study), and memory B cells 80.6% (95%CI 65.0-90.2, one study) and the pooled prevalence of reinfection was 0.2% (95%CI 0.0 – 0.7, I2 = 98.8, 9 studies). Individuals who recovered from COVID-19 had an 81% reduction in odds of a reinfection (OR 0.19, 95% CI 0.1 - 0.3, I2 = 90.5%, 5 studies).Conclusion Around 90% of people previously infected with SARS-CoV-2 had evidence of immunological memory to SARS-CoV-2, which was sustained for at least 6-8 months after recovery, and had a low risk of reinfection.Registration PROSPERO: CRD42020201234Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding to reportAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study is a meta-analysis used already published dataAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are from published studies